Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Biomedical Sciences
doi 10.11648/j.bs.20170302.12
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Science Publishing Group

Related search

FBXO11 Targets BCL6 for Degradation and Is Inactivated in Diffuse Large B-Cell Lymphomas

Nature
Multidisciplinary
2012English

Lenalidomide in Diffuse Large B-Cell Lymphomas

Advances in Hematology
Hematology
2012English

Microenvironment Expression in Diffuse Large B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Diffuse Large B-Cell Lymphomas Are Metabolically Heterogeneous

Cancer Discovery
Oncology
2012English

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Oncologist
Cancer ResearchMedicineOncology
2018English

A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas

Medical Journal Armed Forces India
Medicine
2011English

The Heat Shock Protein 90 Inhibitor IPI-504 Induces Apoptosis of AKT-dependent Diffuse Large B-Cell Lymphomas

British Journal of Haematology
Hematology
2009English

Prognostic Significance of in Situ Phenotypic Marker Expression in Diffuse Large B-Cell Lymphomas

Biomarker Insights
BiochemistryMolecular MedicinePharmacology
2007English

Reflectance Confocal Microscopy in the Diagnosis of Primary Cutaneous Diffuse Large B-Cell Lymphomas

ROMANIAN JOURNAL OF CLINICAL AND EXPERIMENTAL DERMATOLOGY
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy